Peer-reviewed veterinary case report
Adipokine levels in overweight dogs with pituitary-dependent
By Cho, K-D et al.Ā·Published in Journal of veterinary internal medicineĀ·2014Ā·College of Veterinary Medicine, South KoreaĀ·View original on PubMed ā
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research ā every detail traces back to the citation above. How we work ā
Original publication title: Serum adipokine concentrations in dogs with naturally occurring pituitary-dependent hyperadrenocorticism.
- Species:
- dog
Plain-English summary
A group of overweight dogs with pituitary-dependent hyperadrenocorticism (PDH) had higher levels of certain hormones, specifically leptin and insulin, compared to healthy dogs. Nine of these dogs were treated with a medication called trilostane, which helped lower their leptin and insulin levels, but these levels remained higher than those in healthy dogs even after treatment. This suggests that while trilostane can help manage some symptoms, dogs with PDH may still have ongoing hormonal imbalances. If your dog is diagnosed with PDH, it's important to discuss treatment options with your veterinarian.
People also search for: dog Cushing's disease treatment Ā· overweight dog insulin levels Ā· trilostane for dogs with PDH
Abstract
BACKGROUND: An excess of intra-abdominal fat is observed frequently in dogs with hyperadrenocorticism (HAC). Adipokine dysregulation is a possible cause of complications related to visceral obesity, but little information is available on adipokine in dogs with naturally occurring HAC. OBJECTIVES: To examine the differences in the circulating adipokines concentrations in overweight dogs with and without pituitary-dependent HAC (PDH). ANIMALS: Thirty healthy dogs and 15 client-owned dogs with PDH. METHODS: Case-controlled observational study, which enrolled 15 overweight dogs diagnosed with PDH and 30 otherwise healthy dogs of similar body condition score. Nine of 15 dogs with PDH were treated with low-dose trilostane twice daily and reassessed after treatment. RESULTS: The serum leptin (P < .0001) and insulin (P < .0001) concentrations were significantly higher in the PDH group (leptin, 22.8 ± 8.8 [mean ± SD]; insulin, 9.1 ± 6.1) than the healthy group (leptin, 4.9 ± 3.7; insulin, 1.9 ± 0.9). However, there were no significant differences in the adiponectin, resistin, tumor necrosis factor (TNF)-α, interleukin (IL)-1β, IL-6, IL-10, and IL-18 levels between the 2 groups. In the PDH group, the serum cortisol concentrations had a linear association with the leptin concentrations, and there were significant decreases in the leptin (P = .0039) and insulin (P = .0039) levels after trilostane treatment. However, the leptin and insulin levels remained higher after trilostane treatment than in healthy control dogs with similar body condition score. CONCLUSIONS AND CLINICAL IMPORTANCE: Hypercortisolemia in dogs with PDH might upregulate the circulating leptin levels. However, a large population-based study will be necessary to determine whether the upregulation of leptin is involved directly with the complications caused by HAC.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases āOriginal publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/24372863/